Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other financing activities (2020 - 2025)

Gain Therapeutics has reported Other financing activities over the past 4 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly results put Other financing activities at -$1.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $395477.0 (down 79.51% YoY), and the annual figure for FY2025 was $395478.0, up 40.81%.
  • Other financing activities for Q4 2025 was -$1.0 million at Gain Therapeutics, down from $460793.0 in the prior quarter.
  • Over the last five years, Other financing activities for GANX hit a ceiling of $1.4 million in Q2 2024 and a floor of -$1.0 million in Q4 2025.
  • Median Other financing activities over the past 3 years was $423145.0 (2025), compared with a mean of $353257.1.
  • Peak annual rise in Other financing activities hit 190.88% in 2025, while the deepest fall reached 62.98% in 2025.
  • Gain Therapeutics' Other financing activities stood at $213795.0 in 2021, then soared by 64.65% to $352017.0 in 2024, then plummeted by 389.46% to -$1.0 million in 2025.
  • The last three reported values for Other financing activities were -$1.0 million (Q4 2025), $460793.0 (Q3 2025), and $530499.0 (Q2 2025) per Business Quant data.